AstraZeneca PLC (LSE/STO/NYSE: AZN) announced on 16 November 2026 that the US Food and Drug Administration has approved Klygefa (gefurulimab), developed by its Alexion rare disease unit, for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody positive. The approval makes Klygefa the first and only dual-binding nanobody C5 inhibitor cleared in the US, offering once-weekly subcutaneous self-administration via autoinjector. The decision is supported by pivotal Phase III PREVAIL trial data and extends a regulatory footprint that already includes the European Union and Japan.
Key Points
- AstraZeneca PLC (AZN) — global biopharmaceutical company headquartered in Cambridge, UK
- FDA approved Klygefa (gefurulimab) for AChR antibody-positive adult gMG patients on 16 November 2026
- PREVAIL Phase III primary endpoint met: MG-ADL score improvement of -1.6 versus placebo at week 26 (p<0.0001); clinical benefit observed as early as week one
- Investors may watch for commercial launch progress in the US and regulatory outcomes in China and additional countries
PREVAIL Phase III Trial Data Underpinning the FDA Decision
The FDA approval was based on results from the PREVAIL Phase III trial, a global, randomised, double-blind, placebo-controlled study enrolling 260 patients across 20 countries. Klygefa met its primary endpoint, demonstrating a statistically significant improvement from baseline in the Myasthenia Gravis Activities of Daily Living total score at week 26 compared with placebo, with a treatment difference of -1.6 (95% CI: -2.4, -0.8; p<0.0001). Notably, clinical improvement was observed as early as week one, and gains were sustained through one year. The trial data were published in JAMA Neurology and presented at the AANEM 2025 Annual Meeting.
Klygefa's Dual-Binding Nanobody Mechanism and Once-Weekly Dosing Convenience
Klygefa works by binding to the C5 protein in the terminal complement cascade, inhibiting the overactivation that leads the immune system to attack the neuromuscular junction in gMG patients. Its concurrent binding to serum albumin provides an extended half-life, enabling once-weekly dosing rather than the more frequent administration required by some existing therapies. The autoinjector format supports subcutaneous self-administration at home, which the announcement states is intended to give patients greater autonomy. The safety profile was described as generally consistent with established C5 inhibitors eculizumab and ravulizumab, with the most common adverse events being injection site reactions (12%), back pain (8%), and vomiting (5%).
Estimated 81,000 AChR-Positive gMG Patients Represent the Addressable US Population
Generalised myasthenia gravis is a rare autoimmune disorder causing severe muscle weakness and reduced muscle function. In the US, the announcement states an estimated 98,500 people are diagnosed with gMG, of whom approximately 81,000 are AChR antibody positive — the specific population for which Klygefa is now approved. This positions Alexion, AstraZeneca Rare Disease, to address a substantial portion of the US gMG patient base. Klygefa is already approved in the EU, Japan, and other countries, and regulatory submissions based on PREVAIL results remain under review in China and additional markets, suggesting further potential geographic expansion.
AstraZeneca's Alexion Unit Extends Rare Disease Complement Portfolio With US Launch
Alexion, AstraZeneca Rare Disease, described by the company as a pioneering leader in rare disease for more than three decades, has historically built its portfolio around complement biology, most notably with eculizumab and ravulizumab. Klygefa represents the unit's first approved dual-binding nanobody, adding a differentiated molecule to that established franchise. As part of AstraZeneca — which sells medicines in more than 125 countries — Alexion is headquartered in Boston, US. Investors may monitor the speed and scale of Klygefa's US commercial rollout, as well as forthcoming regulatory decisions in China, as indicators of the product's near-term contribution to AstraZeneca's rare disease revenue base.




Please wait processing your request...